FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949275490> ?p ?o ?g. }

• W2949275490 endingPage "2640" @default.
• W2949275490 startingPage "2634" @default.
• W2949275490 abstract "No AccessJournal of UrologyAdult Urology1 Jun 2009Rapid Efficacy of the Highly Selective α1A-Adrenoceptor Antagonist Silodosin in Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studiesis accompanied byThe Role of α1-Adrenoceptor and Arachidonate Pathways in Increased Tone of Demucosalized Bladder Tissueis companion ofRapid Efficacy of the Highly Selective α1A-Adrenoceptor Antagonist Silodosin in Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studies Leonard S. Marks, Marc C. Gittelman, Lawrence A. Hill, Weining Volinn, and Gary Hoel Leonard S. MarksLeonard S. Marks University of California at Los Angeles and Urological Sciences Research Foundation, Los Angeles, California Financial interest and/or other relationship with Allergan, American Medical Systems, Astellas, Bayer, Beckman Coulter, Diagnostic Ultrasound, GTX, GlaxoSmithKline, Gen-Probe, Indevus, Light Sciences Oncology, Lilly/ICOS, Merck, Novartis, Onconome, Pfizer, Sanofi, Solvay, Watson, National Institutes of Health, CapCURE, Pardee Foundation and Seder Foundation. More articles by this author , Marc C. GittelmanMarc C. Gittelman South Florida Medical Research, Aventura, Florida Financial interest and/or other relationship with Watson Pharmaceuticals. More articles by this author , Lawrence A. HillLawrence A. Hill Watson Laboratories, Salt Lake City, Utah Financial interest and/or other relationship with Watson Pharmaceuticals. More articles by this author , Weining VolinnWeining Volinn Watson Laboratories, Salt Lake City, Utah Financial interest and/or other relationship with Watson Pharmaceuticals. More articles by this author , and Gary HoelGary Hoel Watson Laboratories, Salt Lake City, Utah Financial interest and/or other relationship with Watson Pharmaceuticals. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2009.02.034AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated the efficacy and safety of silodosin for treatment of benign prostatic hyperplasia symptoms in 2 randomized, placebo controlled, phase 3 studies. Materials and Methods: Men 50 years or older with an International Prostate Symptom Score of 13 or greater and peak urinary flow rate of 4 to 15 ml per second received placebo or 8 mg silodosin daily with breakfast for 12 weeks. The primary end point was International Prostate Symptom Score change from baseline to last observation. Change in peak urinary flow rate was a secondary end point. Differences in treatment efficacy were assessed by ANCOVA. Results: Of 923 patients (mean age 65 years) 466 received silodosin and 457 placebo. After 0.5 week (range 3 to 4 days) of treatment patients receiving silodosin vs placebo achieved significant improvement in total International Prostate Symptom Score (difference −1.9, p <0.0001) and irritative (–0.5, p = 0.0002) and obstructive (–1.4, p <0.0001) subscores. The mean ± SD change from baseline in total International Prostate Symptom Score was −4.2 ± 5.3 for silodosin vs −2.3 ± 4.4 for placebo. Differences (silodosin vs placebo) in International Prostate Symptom Score and subscores increased by week 12 (p <0.0001). Mean change from baseline in peak urinary flow rate (ml per second) 2 to 6 hours after initial dose was greater (p <0.0001) with silodosin (2.8 ± 3.4) than placebo (1.5 ± 3.8). Differences remained significant (p <0.001) through week 12. The most common treatment emergent adverse event was (mostly mild) retrograde ejaculation (silodosin 28.1% of patients, placebo 0.9%). Few patients receiving silodosin (2.8%) discontinued because of retrograde ejaculation. Proportions of patients with treatment emergent orthostatic hypotension were similar for silodosin (2.6%) and placebo (1.5%). Conclusions: Treatment with silodosin produced rapid improvement in urinary symptoms that was sustained for 12 weeks. Silodosin was well tolerated with a low incidence of orthostatic hypotension. References 1 : Benign prostatic hyperplasia. In: Urologic Diseases in America. Edited by . Bethesda, MD: National Kidney and Urologic Diseases Information Clearinghouse2007. NIH publication 07-5512: 43-67. Available at: http://kidney.niddk.nih.gov/statistics/uda/ (updated February 2007). Accessed August 28, 2008. Google Scholar 2 : Pathophysiology of lower urinary tract symptoms in the aging male population. Rev Urol2005; 7: S3. Google Scholar 3 : Pharmacology of α1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol2007; 4: 368. Google Scholar 4 : α1-Adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol2008; 15: 193. Google Scholar 5 : Noradrenaline contractions of human prostate mediated by α1A-(α1c-)adrenoceptor subtype. Br J Pharmacol1995; 115: 781. Google Scholar 6 : Pharmacological evidence of distinct α1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol1994; 113: 723. Google Scholar 7 : Tissue selectivity of KMD-3213, an α1-adrenoreceptor antagonist, in human prostate and vasculature. J Urol2000; 164: 578. Link, Google Scholar 8 : Tamsulosin: an overview. World J Urol2002; 19: 397. Google Scholar 9 : A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur Urol1998; 33: 481. Google Scholar 10 : KMD-3213, a novel, potent, α1a-adrenoceptor-selective antagonist: characterization using recombinant human α1-adrenoceptors and native tissues. Mol Pharmacol1995; 48: 250. Google Scholar 11 : In vivo demonstration of α1A-adrenoceptor subtype selectivity of KMD-3213 in rat tissues. J Pharmacol Exp Ther2001; 296: 160. Google Scholar 12 : Effect of KMD-3213, an α1a-adrenoceptor-selective antagonist, on the contractions of rabbit prostate and rabbit and rat aorta. Eur J Pharmacol1996; 315: 73. Google Scholar 13 : KMD-3213, a uroselective and long-acting α1a-adrenoceptor antagonist, tested in a novel rat model. J Pharmacol Exp Ther1999; 291: 81. Google Scholar 14 : MedWatch Web site http://www.fda.gov/medwatch/safety/2001/jun01.htm. (updated June 2001). Accessed August 28, 2008. Google Scholar 15 : Silodosin, a new α1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int2006; 98: 1019. Google Scholar 16 : Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol1999; 36: 335. Google Scholar 17 : Effects of α1-adrenoceptor antagonists on male sexual function. Drugs2006; 66: 287. Google Scholar 18 : Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int2003; 92: 257. Google Scholar 19 : Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia: Tamsulosin Investigator Group. Urology1998; 51: 892. Google Scholar 20 : The long-term outcome of medical therapy for BPH. Eur Urol2007; 51: 1522. Google Scholar 21 : Clinical Guidelines: Management of BPH ('03/Updated '06): Chapter 3 with Appendix: results of the treatment outcomes analyses. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph. Accessed December 3, 2008. Google Scholar © 2009 by American Urological AssociationFiguresReferencesRelatedDetailsCited byLerner L, McVary K, Barry M, Bixler B, Dahm P, Das A, Gandhi M, Kaplan S, Kohler T, Martin L, Parsons J, Roehrborn C, Stoffel J, Welliver C and Wilt T (2021) Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I—Initial Work-up and Medical ManagementJournal of Urology, VOL. 206, NO. 4, (806-817), Online publication date: 1-Oct-2021.Kaplan S (2015) Re: Reasons for Prescription Change of α1-Blockers in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic HyperplasiaJournal of Urology, VOL. 193, NO. 4, (1317-1317), Online publication date: 1-Apr-2015.Kaplan S (2014) Re: Systematic Review and Meta-Analysis of Randomized Controlled Trials Evaluating Silodosin in the Treatment of Non-Neurogenic Male Lower Urinary Tract Symptoms Suggestive of Benign Prostatic EnlargementJournal of Urology, VOL. 193, NO. 3, (948-949), Online publication date: 1-Mar-2015.Kaplan S (2014) Re: Comparison of 7 α1-Adrenoreceptor Antagonists in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia: A Short-Term Crossover StudyJournal of Urology, VOL. 192, NO. 4, (1166-1167), Online publication date: 1-Oct-2014.Nickel J, O'Leary M, Lepor H, Caramelli K, Thomas H, Hill L and Hoel G (2011) Silodosin for Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Results of a Phase II Multicenter, Double-Blind, Placebo Controlled StudyJournal of Urology, VOL. 186, NO. 1, (125-131), Online publication date: 1-Jul-2011.Kaplan S (2015) Re: Reasons for Prescription Change of α1-Blockers in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic HyperplasiaJournal of Urology, Related articlesJournal of Urology17 Apr 2009The Role of α1-Adrenoceptor and Arachidonate Pathways in Increased Tone of Demucosalized Bladder TissueJournal of Urology10 Nov 2018Rapid Efficacy of the Highly Selective α1A-Adrenoceptor Antagonist Silodosin in Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studies Volume 181Issue 6June 2009Page: 2634-2640 Advertisement Copyright & Permissions© 2009 by American Urological AssociationKeywordsprostatic hyperplasiaKMD 3213signs and symptomsAcknowledgmentsRoland Tacke, PhD and Marsha Hall from Scientific Connexions (Newtown, Pennsylvania) provided assistance with funding from Watson Pharma, Inc.MetricsAuthor Information Leonard S. Marks University of California at Los Angeles and Urological Sciences Research Foundation, Los Angeles, California Financial interest and/or other relationship with Allergan, American Medical Systems, Astellas, Bayer, Beckman Coulter, Diagnostic Ultrasound, GTX, GlaxoSmithKline, Gen-Probe, Indevus, Light Sciences Oncology, Lilly/ICOS, Merck, Novartis, Onconome, Pfizer, Sanofi, Solvay, Watson, National Institutes of Health, CapCURE, Pardee Foundation and Seder Foundation. More articles by this author Marc C. Gittelman South Florida Medical Research, Aventura, Florida Financial interest and/or other relationship with Watson Pharmaceuticals. More articles by this author Lawrence A. Hill Watson Laboratories, Salt Lake City, Utah Financial interest and/or other relationship with Watson Pharmaceuticals. More articles by this author Weining Volinn Watson Laboratories, Salt Lake City, Utah Financial interest and/or other relationship with Watson Pharmaceuticals. More articles by this author Gary Hoel Watson Laboratories, Salt Lake City, Utah Financial interest and/or other relationship with Watson Pharmaceuticals. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2949275490 created "2019-06-27" @default.
• W2949275490 creator A5003945364 @default.
• W2949275490 creator A5037831869 @default.
• W2949275490 creator A5041384721 @default.
• W2949275490 creator A5086765650 @default.
• W2949275490 creator A5086512125 @default.
• W2949275490 date "2009-06-01" @default.
• W2949275490 modified "2023-10-14" @default.
• W2949275490 title "Rapid Efficacy of the Highly Selective α _1A -Adrenoceptor Antagonist Silodosin in Men With Signs and Symptoms of Benign Prostatic Hyperplasia: Pooled Results of 2 Phase 3 Studies" @default.
• W2949275490 cites W1489169544 @default.
• W2949275490 cites W1970782054 @default.
• W2949275490 cites W2018373111 @default.
• W2949275490 cites W2021270740 @default.
• W2949275490 cites W2029197057 @default.
• W2949275490 cites W2033685093 @default.
• W2949275490 cites W2042712431 @default.
• W2949275490 cites W2056264466 @default.
• W2949275490 cites W2067746505 @default.
• W2949275490 cites W2077358279 @default.
• W2949275490 cites W2083289681 @default.
• W2949275490 cites W2100007591 @default.
• W2949275490 cites W2135421268 @default.
• W2949275490 cites W4321059165 @default.
• W2949275490 doi "https://doi.org/10.1016/j.juro.2009.02.034" @default.
• W2949275490 hasPublicationYear "2009" @default.
• W2949275490 type Work @default.
• W2949275490 sameAs 2949275490 @default.
• W2949275490 citedByCount "129" @default.
• W2949275490 countsByYear W29492754902012 @default.
• W2949275490 countsByYear W29492754902013 @default.
• W2949275490 countsByYear W29492754902014 @default.
• W2949275490 countsByYear W29492754902015 @default.
• W2949275490 countsByYear W29492754902016 @default.
• W2949275490 countsByYear W29492754902017 @default.
• W2949275490 countsByYear W29492754902018 @default.
• W2949275490 countsByYear W29492754902019 @default.
• W2949275490 countsByYear W29492754902020 @default.
• W2949275490 countsByYear W29492754902021 @default.
• W2949275490 countsByYear W29492754902022 @default.
• W2949275490 countsByYear W29492754902023 @default.
• W2949275490 crossrefType "journal-article" @default.
• W2949275490 hasAuthorship W2949275490A5003945364 @default.
• W2949275490 hasAuthorship W2949275490A5037831869 @default.
• W2949275490 hasAuthorship W2949275490A5041384721 @default.
• W2949275490 hasAuthorship W2949275490A5086512125 @default.
• W2949275490 hasAuthorship W2949275490A5086765650 @default.
• W2949275490 hasConcept C121608353 @default.
• W2949275490 hasConcept C126322002 @default.
• W2949275490 hasConcept C126894567 @default.
• W2949275490 hasConcept C170493617 @default.
• W2949275490 hasConcept C2776235491 @default.
• W2949275490 hasConcept C2776885963 @default.
• W2949275490 hasConcept C2777562237 @default.
• W2949275490 hasConcept C2779161064 @default.
• W2949275490 hasConcept C2779478474 @default.
• W2949275490 hasConcept C3018875020 @default.
• W2949275490 hasConcept C71924100 @default.
• W2949275490 hasConceptScore W2949275490C121608353 @default.
• W2949275490 hasConceptScore W2949275490C126322002 @default.
• W2949275490 hasConceptScore W2949275490C126894567 @default.
• W2949275490 hasConceptScore W2949275490C170493617 @default.
• W2949275490 hasConceptScore W2949275490C2776235491 @default.
• W2949275490 hasConceptScore W2949275490C2776885963 @default.
• W2949275490 hasConceptScore W2949275490C2777562237 @default.
• W2949275490 hasConceptScore W2949275490C2779161064 @default.
• W2949275490 hasConceptScore W2949275490C2779478474 @default.
• W2949275490 hasConceptScore W2949275490C3018875020 @default.
• W2949275490 hasConceptScore W2949275490C71924100 @default.
• W2949275490 hasIssue "6" @default.
• W2949275490 hasLocation W29492754901 @default.
• W2949275490 hasOpenAccess W2949275490 @default.
• W2949275490 hasPrimaryLocation W29492754901 @default.
• W2949275490 hasRelatedWork W1522824028 @default.
• W2949275490 hasRelatedWork W2039349201 @default.
• W2949275490 hasRelatedWork W2073495245 @default.
• W2949275490 hasRelatedWork W2097551154 @default.
• W2949275490 hasRelatedWork W2299624252 @default.
• W2949275490 hasRelatedWork W2562032665 @default.
• W2949275490 hasRelatedWork W2809321399 @default.
• W2949275490 hasRelatedWork W2811320370 @default.
• W2949275490 hasRelatedWork W3006661056 @default.
• W2949275490 hasRelatedWork W2779678079 @default.
• W2949275490 hasVolume "181" @default.
• W2949275490 isParatext "false" @default.
• W2949275490 isRetracted "false" @default.
• W2949275490 magId "2949275490" @default.
• W2949275490 workType "article" @default.